Comparative efficacy of axitinib versus sorafenib for advanced renal cell carcinoma

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [31] SORAFENIB VERSUS AXITINIB FOR SECOND-LINE TREATMENT OF SUNITINIB-REFRACTORY PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC) IN THE UNITED STATES (US)
    Ozer-Stillman, I.
    Keyser, R.
    Ambavane, A.
    Cislo, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 283 - 283
  • [32] Axitinib In Advanced, Treatment-Experienced Renal Cell Carcinoma
    Yang, Lily P. H.
    McKeage, Kate
    DRUGS, 2012, 72 (18) : 2375 - 2384
  • [33] Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 693 - 703
  • [34] Targeted treatments in advanced renal cell carcinoma: focus on axitinib
    Verzoni, Elena
    Grassi, Paolo
    Testa, Isabella
    Iacovelli, Roberto
    Biondani, Pamela
    Garanzini, Enrico
    De Braud, Filippo
    Procopio, Giuseppe
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 107 - 116
  • [35] Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
    Ansari, Jawaher
    Hussain, Syed A.
    Ansari, Asif
    Glaholm, John
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 39 - 46
  • [36] Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy
    Leslie, Isla
    Boos, Laura Amanda
    Larkin, James
    Pickering, Lisa
    EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (05) : 343 - 354
  • [37] EFFICACY OF SORAFENIB IN ADVANCED RENAL CELL CARCINOMA INDEPENDENT OF PROGNOSTIC GROUP AND HISTOLOGY SUBTYPES
    Tafreshi, A.
    Thientosapol, E.
    Liew, M. S.
    Guo, Y.
    Quaggiotto, M.
    Boyer, M.
    Davis, I.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 31 - 31
  • [38] Axitinib combination therapies versus sunitinib for renal cell carcinoma
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (03): : E141 - E141
  • [39] AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS
    Motzer, R. J.
    Escudier, B.
    Tomczak, P.
    Negrier, S.
    Gore, M. E.
    Tarazi, J.
    Hariharan, S.
    Rosbrook, B.
    Kim, S.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 262 - 262
  • [40] The efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: Real-world data of sorafenib in Japan
    Tatsugami, K.
    Oya, M.
    Kabu, K.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2017, 28
12345